Biocon Ltd is looking to be the top domestic player in the growing segment in the next 4-5 years. Its erythropoietin (EPO) brand to treat anaemia in renal failure patients is alone aimed to be number one in 3-5 years with 30 per cent market share. The red blood cell enriching product is among 18 competing brands, among them nine pre-filled syringes (PFSs). It is also the biggest EPO producer in the country. The nephrology range with six branded products was unveiled in March 2007 and at least as many as said to be coming out over the next three years. These formulations, currently giving about 8 per cent of the company''s revenues, are hoped to grow to 15 per cent next year. The portfolio comprise Renodapt - S (mycophenolate sodium); Renodapt (mycophenolate mofetil); Cyclophil ME (cyclosporine) Tacrograf (Tacrolimus) and Erypro Safe.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment